BIOMAT Database Logo BIOMAT Database Logo

Some effects of hydralazine on hypertensive patients with impaired kidney function. 1968

H Spechtmeyer, and S V Krees, and F W Wolff

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006830 Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Hydrallazin,Apresoline,Apressin,Apressoline,Hydralazine Hydrochloride,Hydralazine mono-Hydrochloride,Hydrazinophthalazine,Nepresol,Hydralazine mono Hydrochloride,Hydrochloride, Hydralazine,mono-Hydrochloride, Hydralazine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

H Spechtmeyer, and S V Krees, and F W Wolff
Immunologic effects of hydralazine in hypertensive patients.
August 1981, Arthritis and rheumatism,
H Spechtmeyer, and S V Krees, and F W Wolff
Effects of nadolol and propranolol on renal function in hypertensive patients with moderately impaired renal function.
October 1985, British journal of clinical pharmacology,
H Spechtmeyer, and S V Krees, and F W Wolff
Pharmacodynamics and kinetics of etozolin/ozolinone in hypertensive patients with normal and impaired kidney function.
January 1984, European journal of clinical pharmacology,
H Spechtmeyer, and S V Krees, and F W Wolff
Prospective study of immunologic effects of hydralazine in hypertensive patients.
April 1981, Clinical pharmacology and therapeutics,
H Spechtmeyer, and S V Krees, and F W Wolff
Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients.
August 1993, Journal of cardiovascular pharmacology,
H Spechtmeyer, and S V Krees, and F W Wolff
Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients.
February 1996, Diabetes,
H Spechtmeyer, and S V Krees, and F W Wolff
Estimating baseline kidney function in hospitalized patients with impaired kidney function.
May 2012, Clinical journal of the American Society of Nephrology : CJASN,
H Spechtmeyer, and S V Krees, and F W Wolff
Estimating baseline kidney function in hospitalized patients with impaired kidney function.
January 2013, Annals of clinical biochemistry,
H Spechtmeyer, and S V Krees, and F W Wolff
Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results.
May 1984, The Journal of antimicrobial chemotherapy,
H Spechtmeyer, and S V Krees, and F W Wolff
Some consequences of drug choice and dosage regimen for patients with impaired kidney function.
April 1983, Drug intelligence & clinical pharmacy,
Copied contents to your clipboard!